Avid Bioservices, Inc. (CDMO)
| Previous Close | 6.68 |
| Open | 6.68 |
| Bid | 6.78 x 200 |
| Ask | 6.89 x 100 |
| Day's Range | 6.68 - 6.88 |
| 52 Week Range | 4.07 - 18.86 |
| Volume | |
| Avg. Volume | 1,333,633 |
| Market Cap | 431M |
| Beta (5Y Monthly) | 1.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.18 |
| Earnings Date | Apr 24, 2024 - Apr 26, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.25 |
GlobeNewswireAvid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q
TUSTIN, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (Nasdaq:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today it received a notice (the “Notice”) on March 19, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure t
- GuruFocus.com
Avid Bioservices Inc (CDMO) Releases Preliminary Q3 Financial Results
Insights into Revenue, Gross Profit, and Operational Performance
- GlobeNewswire
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the “2029 Notes”). In connection with the offering, the company entered into private placement purchase agreements with the several purchasers, each of whom is a “qualified institutional buyer” within the meaning o
